Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers

Hong In Yoon, Woong Sub Koom, Yong Bae Kim, Byung Soh Min, Kang Young Lee, Nam Kyu Kim, Sang Joon Shin, Joong Bae Ahn, Ki Chang Keum

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To investigate the role of biomarkers including serum tissue inhibitor of metalloproteinases-1 (TIMP-1), urokinase plasminogen activator receptor, vascular endothelial growth factor, and epidermal growth factor receptor in predicting pathologic response to neoadjuvant chemoradiation (NACRT) for rectal cancer. Methods: Between 2007 and 2009, 50 clinical TNM stage II or III patients were analyzed in this prospective study. Pre- and post-NACRT serum levels of biomarkers were assessed using ELISAs. The primary and secondary endpoints were pathologic complete response (pCR) and Mandard regression grade (MRG). Results: The pCR was reported in 5 patients (10.0 %). According to the MRG, fifteen patients (30.0 %) were divided into group A (Grade I-II), the others in group B (Grade III-V). On univariate analysis, post-NACRT TIMP-1 showed notable significance with pCR (P = 0.092) and significant correlation with MRG group A (P = 0.003). Post-NACRT TIMP-1 ≤ 204.5 ng/mL as cut-off value by ROC curve was associated with more pCR and MRG group A patients (P = 0.016 and 0.002). Interval between NACRT and surgery was related to pCR with approached trend levels of significance (P = 0.05) and to MRG group A significantly on univariate analysis of clinical factors (P = 0.031). On multivariate analysis, post-NACRT TIMP-1 was not significantly related to pCR (P = 0.187), while it was significantly associated with MRG (P = 0.009). Among clinical responders, post-NACRT TIMP-1 level ≤ 204.5 ng/mL was significantly associated with pCR (P = 0.021) and MRG group A (P = 0.003). Conclusions: Post-NACRT serum TIMP-1 could be used as a predictive marker of pathologic response to NACRT in rectal cancer, even in patients with clinical response.

Original languageEnglish
Pages (from-to)399-409
Number of pages11
JournalJournal of cancer research and clinical oncology
Volume140
Issue number3
DOIs
Publication statusPublished - 2014 Mar 1

Fingerprint

Tissue Inhibitor of Metalloproteinase-1
Rectal Neoplasms
Biomarkers
Enzyme-Linked Immunosorbent Assay
Serum
Urokinase Plasminogen Activator Receptors
Epidermal Growth Factor Receptor
ROC Curve
Vascular Endothelial Growth Factor A
Statistical Factor Analysis
Multivariate Analysis
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{5268cf54c62941eaa0e36ca12238b0dc,
title = "Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers",
abstract = "Purpose: To investigate the role of biomarkers including serum tissue inhibitor of metalloproteinases-1 (TIMP-1), urokinase plasminogen activator receptor, vascular endothelial growth factor, and epidermal growth factor receptor in predicting pathologic response to neoadjuvant chemoradiation (NACRT) for rectal cancer. Methods: Between 2007 and 2009, 50 clinical TNM stage II or III patients were analyzed in this prospective study. Pre- and post-NACRT serum levels of biomarkers were assessed using ELISAs. The primary and secondary endpoints were pathologic complete response (pCR) and Mandard regression grade (MRG). Results: The pCR was reported in 5 patients (10.0 {\%}). According to the MRG, fifteen patients (30.0 {\%}) were divided into group A (Grade I-II), the others in group B (Grade III-V). On univariate analysis, post-NACRT TIMP-1 showed notable significance with pCR (P = 0.092) and significant correlation with MRG group A (P = 0.003). Post-NACRT TIMP-1 ≤ 204.5 ng/mL as cut-off value by ROC curve was associated with more pCR and MRG group A patients (P = 0.016 and 0.002). Interval between NACRT and surgery was related to pCR with approached trend levels of significance (P = 0.05) and to MRG group A significantly on univariate analysis of clinical factors (P = 0.031). On multivariate analysis, post-NACRT TIMP-1 was not significantly related to pCR (P = 0.187), while it was significantly associated with MRG (P = 0.009). Among clinical responders, post-NACRT TIMP-1 level ≤ 204.5 ng/mL was significantly associated with pCR (P = 0.021) and MRG group A (P = 0.003). Conclusions: Post-NACRT serum TIMP-1 could be used as a predictive marker of pathologic response to NACRT in rectal cancer, even in patients with clinical response.",
author = "Yoon, {Hong In} and Koom, {Woong Sub} and Kim, {Yong Bae} and Min, {Byung Soh} and Lee, {Kang Young} and Kim, {Nam Kyu} and Shin, {Sang Joon} and Ahn, {Joong Bae} and Keum, {Ki Chang}",
year = "2014",
month = "3",
day = "1",
doi = "10.1007/s00432-013-1578-y",
language = "English",
volume = "140",
pages = "399--409",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "3",

}

Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers. / Yoon, Hong In; Koom, Woong Sub; Kim, Yong Bae; Min, Byung Soh; Lee, Kang Young; Kim, Nam Kyu; Shin, Sang Joon; Ahn, Joong Bae; Keum, Ki Chang.

In: Journal of cancer research and clinical oncology, Vol. 140, No. 3, 01.03.2014, p. 399-409.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers

AU - Yoon, Hong In

AU - Koom, Woong Sub

AU - Kim, Yong Bae

AU - Min, Byung Soh

AU - Lee, Kang Young

AU - Kim, Nam Kyu

AU - Shin, Sang Joon

AU - Ahn, Joong Bae

AU - Keum, Ki Chang

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Purpose: To investigate the role of biomarkers including serum tissue inhibitor of metalloproteinases-1 (TIMP-1), urokinase plasminogen activator receptor, vascular endothelial growth factor, and epidermal growth factor receptor in predicting pathologic response to neoadjuvant chemoradiation (NACRT) for rectal cancer. Methods: Between 2007 and 2009, 50 clinical TNM stage II or III patients were analyzed in this prospective study. Pre- and post-NACRT serum levels of biomarkers were assessed using ELISAs. The primary and secondary endpoints were pathologic complete response (pCR) and Mandard regression grade (MRG). Results: The pCR was reported in 5 patients (10.0 %). According to the MRG, fifteen patients (30.0 %) were divided into group A (Grade I-II), the others in group B (Grade III-V). On univariate analysis, post-NACRT TIMP-1 showed notable significance with pCR (P = 0.092) and significant correlation with MRG group A (P = 0.003). Post-NACRT TIMP-1 ≤ 204.5 ng/mL as cut-off value by ROC curve was associated with more pCR and MRG group A patients (P = 0.016 and 0.002). Interval between NACRT and surgery was related to pCR with approached trend levels of significance (P = 0.05) and to MRG group A significantly on univariate analysis of clinical factors (P = 0.031). On multivariate analysis, post-NACRT TIMP-1 was not significantly related to pCR (P = 0.187), while it was significantly associated with MRG (P = 0.009). Among clinical responders, post-NACRT TIMP-1 level ≤ 204.5 ng/mL was significantly associated with pCR (P = 0.021) and MRG group A (P = 0.003). Conclusions: Post-NACRT serum TIMP-1 could be used as a predictive marker of pathologic response to NACRT in rectal cancer, even in patients with clinical response.

AB - Purpose: To investigate the role of biomarkers including serum tissue inhibitor of metalloproteinases-1 (TIMP-1), urokinase plasminogen activator receptor, vascular endothelial growth factor, and epidermal growth factor receptor in predicting pathologic response to neoadjuvant chemoradiation (NACRT) for rectal cancer. Methods: Between 2007 and 2009, 50 clinical TNM stage II or III patients were analyzed in this prospective study. Pre- and post-NACRT serum levels of biomarkers were assessed using ELISAs. The primary and secondary endpoints were pathologic complete response (pCR) and Mandard regression grade (MRG). Results: The pCR was reported in 5 patients (10.0 %). According to the MRG, fifteen patients (30.0 %) were divided into group A (Grade I-II), the others in group B (Grade III-V). On univariate analysis, post-NACRT TIMP-1 showed notable significance with pCR (P = 0.092) and significant correlation with MRG group A (P = 0.003). Post-NACRT TIMP-1 ≤ 204.5 ng/mL as cut-off value by ROC curve was associated with more pCR and MRG group A patients (P = 0.016 and 0.002). Interval between NACRT and surgery was related to pCR with approached trend levels of significance (P = 0.05) and to MRG group A significantly on univariate analysis of clinical factors (P = 0.031). On multivariate analysis, post-NACRT TIMP-1 was not significantly related to pCR (P = 0.187), while it was significantly associated with MRG (P = 0.009). Among clinical responders, post-NACRT TIMP-1 level ≤ 204.5 ng/mL was significantly associated with pCR (P = 0.021) and MRG group A (P = 0.003). Conclusions: Post-NACRT serum TIMP-1 could be used as a predictive marker of pathologic response to NACRT in rectal cancer, even in patients with clinical response.

UR - http://www.scopus.com/inward/record.url?scp=84896705442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896705442&partnerID=8YFLogxK

U2 - 10.1007/s00432-013-1578-y

DO - 10.1007/s00432-013-1578-y

M3 - Article

C2 - 24390211

AN - SCOPUS:84896705442

VL - 140

SP - 399

EP - 409

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 3

ER -